Pancreatic Cancer Research

ResearcherChiba Cancer Center Research InstituteNo recent work listed

Hirokazu Sugimoto

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5027999009. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper

Papers 3

  1. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. First author DOI 10.1038/oncsis.2016.40↗
  2. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Co-author DOI 10.1038/cddis.2015.242↗
  3. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Co-author DOI 10.1038/cddiscovery.2015.10↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mizuyo Nakamura · 3 shared papers, 2015–2016 · strength 0.15
  2. Toshinori Ozaki · 3 shared papers, 2015–2016 · strength 0.15
  3. Osamu Shimozato · 3 shared papers, 2015–2016 · strength 0.15
  4. Meijie Sang · 2 shared papers, 2015–2016 · strength 0.11
  5. Hiroki Nagase · 2 shared papers, 2015 · strength 0.10
  6. Meixiang Sang · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.